CoChat

Regulatory Frameworks for Clinical Trial Data Sharing: Scoping Review

Open access

Published version of a preprint

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Background: Although well recognized for its scientific value, data sharing from clinical trials remains limited. Steps toward harmonization and standardization are increasing in various pockets of the global scientific community. This issue has gained salience during the COVID-19 pandemic. Even for agencies willing to share data, data exclusivity practices complicate matters; strict regulations by funders affect this even further. Finally, many low- and middle-income countries (LMICs) have weaker institutional mechanisms. This complex of factors hampers research and rapid response during public health emergencies. This drew our attention to the need for a review of the regulatory landscape governing clinical trial data sharing. Objective: This review seeks to identify regulatory frameworks and policies that govern clinical trial data sharing and explore key elements of data-sharing mechanisms as outlined in existing regulatory documents. Following from, and based on, this empirical analysis of gaps in existing policy frameworks, we aimed to suggest focal areas for policy interventions on a systematic basis to facilitate clinical trial data sharing. Methods: We followed the JBI scoping review approach. Our review covered electronic databases and relevant gray literature through a targeted web search. We included records (all publication types, except for conference abstracts) available in English that describe clinical trial data–sharing policies, guidelines, or standard operating procedures. Data extraction was performed independently by 2 authors, and findings were summarized using a narrative synthesis approach. Results: We identified 4 articles and 13 policy documents; none originated from LMICs. Most (11/17, 65%) of the clinical trial agencies mandated a data-sharing agreement; 47% (8/17) of these policies required informed consent by trial participants; and 71% (12/17) outlined requirements for a data-sharing proposal review committee. Data-sharing policies have, a priori, milestone-based timelines when clinical trial data can be shared. We classify clinical trial agencies as following either controlled- or open-access data-sharing models. Incentives to promote data sharing and distinctions between mandated requirements and supportive requirements for informed consent during the data-sharing process remain gray areas, needing explication. To augment participant privacy and confidentiality, a neutral institutional mechanism to oversee dissemination of information from the appropriate data sets and more policy interventions led by LMICs to facilitate data sharing are strongly recommended. Conclusions: Our review outlines the immediate need for developing a pragmatic data-sharing mechanism that aims to improve research and innovations as well as facilitate cross-border collaborations. Although a one-policy-fits-all approach would not account for regional and subnational legislation, we suggest that a focus on key elements of data-sharing mechanisms can be used to inform the development of flexible yet comprehensive data-sharing policies so that institutional mechanisms rather than disparate efforts guide data generation, which is the foundation of all scientific endeavor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2196/33591

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 chart. SOP: standard operating procedure.
Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 chart. SOP: standard operating procedure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. 't Hoen, EF, 2009, The global politics of pharmaceutical monopoly power: drug patents, access, innovation. The application of the WTO Doha declaration on TRIPS public health
  2. 2013, Sharing clinical research data: workshop summary
  3. Chakrabarti, G, 2014, J Intellect Prop Rights, 19, 325

Cited by

See all 32

Metadata

Authors
Gudi, N., Kamath, P., Chakraborty, T., Jacob, A. G., Parsekar, S. S., Sarbadhikari, S. N., & John, O.
Affiliations
  • George Institute for Global Health (IN)
  • Manipal Academy of Higher Education (IN)
Corresponding author
John, Oommen
Venue
Journal of Medical Internet Research
Published
2022-05-04
Volume
24
Issue
5
Pages
e33591
ISSN
1438-8871 (ISSN-L)
OpenAlex
W4229049670
Cited by
31
References
53
Citations by year
2026: 9 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 2
FWCI
0.69
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Medical Internet Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
World Health Organization (COVID-19, P20-00060)
Topics
  • Physical Sciences › Computer Science › Information Systems › Research Data Management Practices
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
  • Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
Keywords
clinical trial data sharing, regulatory framework, data sharing policy, data sharing agreements, informed consent, data exclusivity, open access data sharing, low- and middle-income countries, COVID-19 pandemic, public health emergencies, research collaboration, data sharing incentives, harmonization
MeSH terms
COVID-19, Humans, Informed Consent, Poverty, Information Dissemination, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.